BRAND

BEAUTY WELLNESS BRAND

  •  

Core Competencies

core

Ultra-fast PCR Technology Ideal for On-site Molecular Testing

Long turn around time of PCR (Polymerase Chain Reaction) test and its bulky and heavy instrumentation have been the key factors limiting the spread of this highly precise and sensitive detection method in point-of-care diagnostic applications Genesystem invented a microfluidic chip based PCR method associated with compact and sophisticated hardware mechanism which dramatically reduces the TAT of PCR testing down under 20 minutes. Based on this core technology, Genesy stem has commercialized PCR platforms to target on-site testing applications outside the laboratory environments as well as general molecular testing applications.

core

Miniaturized Heating Element for Handy Molecular Testing Platform

Long turn around time of PCR (Polymerase Chain Reaction) test and its bulky and heavy instrumentation have been the key factors limiting the spread of this highly precise and sensitive detection method in point-of-care diagnostic applications. Genesystem invented a microfluidic chip based PCR method associated with compact and sophisticated hardware mechanism which dramatically reduces the TAT of PCR testing down under 20 minutes. Based on this core technology, Genesy stem has commercialized PCR platforms to target on-site testing applications outside the laboratory environments as well as general molecular testing applications.

Biochip Technology Enabling Multiplex or High Multiplex Detection

Adding to the standard PCR chip products, Genesystem is proud to commercialize multiplex testing chip format which is utilizing its unique biochip designing and manufacturing capability. This multiplex testing chip is intended for detecting multiple targets up to 10 from single sample. In this format, target specific primer pairs are labeled on the internal surface of the chip and get activated when the sample is loaded and heated during PCR process. This new multiplexing format provides highly precise and sensitive detection capability of assays as it fundamentally prevents the possibility of primer competition which is a common disadvantage of conventional multiplex PCR method. Genesystem owns innovative technology enabling high multiplex detection which is essential component to design syndromic disease diagnostics panel. The key of this technology is solidifying primer pairs which is labeled on the internal surface of the biochip designed by Genesystem. Genesystem can customize the design of the high multiplex detection biochip for the target numbers up to 100 depending on its client’s panel design.

core_img03